These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 38683278

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G, Croop R, Kudrow D, Halverson P, Lovegren M, Thiry AC, Conway CM, Coric V, Lipton RB.
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The sense of stopping migraine prophylaxis.
    Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K, Onan D, Pensato U, Storch E, Torrente A, Waliszewska-Prosół M, Reuter U, European Headache Federation School of Advanced Studies (EHF-SAS).
    J Headache Pain; 2023 Feb 16; 24(1):9. PubMed ID: 36792981
    [Abstract] [Full Text] [Related]

  • 7. Can calcitonin gene-related peptide monoclonal antibodies ameliorate writer's cramp and migraine?
    Suzuki K, Suzuki S, Fujita H, Sakuramoto H, Shioda M, Hirata K.
    Neuropsychopharmacol Rep; 2024 Jun 16; 44(2):482-484. PubMed ID: 38602109
    [Abstract] [Full Text] [Related]

  • 8. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
    Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E.
    Headache; 2018 Nov 16; 58(10):1689-1696. PubMed ID: 30426478
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
    Overeem LH, Raffaelli B, Mecklenburg J, Kelderman T, Neeb L, Reuter U.
    CNS Drugs; 2021 Aug 16; 35(8):805-820. PubMed ID: 34272688
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Developments in targeting calcitonin gene-related peptide.
    Alabbad S, Figueredo N, Yuan H, Silberstein S.
    Expert Rev Neurother; 2024 May 16; 24(5):477-485. PubMed ID: 38557226
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Novel migraine treatment with CGRP-related monoclonal antibodies].
    Shibata M.
    Rinsho Shinkeigaku; 2020 Oct 24; 60(10):668-676. PubMed ID: 32893246
    [Abstract] [Full Text] [Related]

  • 17. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L, Talon B, Sullivan C, Anderson C, Kymes S, Regnier SA, Soni-Brahmbhatt S, Nahas SJ.
    J Headache Pain; 2023 Aug 02; 24(1):101. PubMed ID: 37532991
    [Abstract] [Full Text] [Related]

  • 18. Recent advances in targeting calcitonin gene-related peptide for the treatment of menstrual migraine: A narrative review.
    Jiang Y, Huang ZL.
    Medicine (Baltimore); 2022 Jun 17; 101(24):e29361. PubMed ID: 35713436
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.